McKesson (MCK)
(Delayed Data from NYSE)
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 6:16 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 6:16 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down
by Zacks Equity Research
Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.
Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.
GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve
by Zacks Equity Research
GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
5 Dividend Growth Stocks to Buy for a Safe Portfolio
by Sweta Killa
Installed Building Products (IBP), PACCAR. (PCAR), McKesson (MCK), Republic Services (RSG) and PulteGroup (PHM) seem solid choices for a safe portfolio amid the current market volatility.
IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.
McKesson Corporation (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much You'd Have If You Invested $1000 in McKesson a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.
Exploring Analyst Estimates for McKesson (MCK) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Intuitive Surgical (ISRG) Q4 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosts procedure sales.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group
by Zacks Equity Research
McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.
McKesson Corporation (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.
If You Invested $1000 in McKesson a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.